Synchronous colorectal cancer

• Authors: Paweł Kozieł , Katarzyna Walkiewicz , Martyna Bednarczyk , Teresa Kokot , Małgorzata Muc-Wierzgoń , Ewa Nowakowska-Zajdel
• Languages of publication: EN

Abstracts

EN

Colorectal cancer is one of the most common neoplasms worldwide. It is still characterized by high mortality and causes ¼ of deaths due to neoplasms. Synchronous cancer is defined as presence of more than one cancer focus (not metastatic) in a patient at the same time. Prevalence of synchronous cancer amounts to 1.1–8.1% of all colorectal carcinomas. More often it affects elderly people and men. Risk factors include inflammatory bowel diseases, hereditary non-polyposis colorectal cancer and familial adenomatous polyposis. Molecular mechanisms underlying the synchronous lesions are: microsatellite instability (MSI), P53 and KRAS mutations as well as glutathione S transferase mutations (GST). In this article, we present a case of a 76-year-old woman with synchronous colorectal cancer in the form of tumors of the sigmoid colon and the ascending colon with metastasis in the liver.

Keywords

EN

colorectal cancer; hepatic metastases; synchronous cancer

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2015
• Volume: 5
• Issue: 4
• Pages: A155-159

Contributors

author

Paweł Kozieł

• Clinical Department of Internal Medicine, Department of Public Health in Bytom, Medical University of Silesia Specialized Hospital no. 1 in Bytom, Poland

author

Katarzyna Walkiewicz

• Clinical Department of Internal Medicine, Department of Public Health in Bytom, Medical University of Silesia Specialized Hospital no. 1 in Bytom, Poland

author

Martyna Bednarczyk

• Clinical Department of Internal Medicine, Department of Public Health in Bytom, Medical University of Silesia Specialized Hospital no. 1 in Bytom, Poland

author

Teresa Kokot

• Clinical Department of Internal Medicine, Department of Public Health in Bytom, Medical University of Silesia Specialized Hospital no. 1 in Bytom, Poland

author

Małgorzata Muc-Wierzgoń

• Clinical Department of Internal Medicine, Department of Public Health in Bytom, Medical University of Silesia Specialized Hospital no. 1 in Bytom, Poland

author

Ewa Nowakowska-Zajdel

• Clinical Department of Internal Medicine, Department of Public Health in Bytom, Medical University of Silesia Specialized Hospital no. 1 in Bytom, Poland

References

• 1. Krajowy Rejestr Nowotworów (KRN, National Cancer Registry) [online: http://onkologia.org.pl/]. Access: April 2015.
• 2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-1403.
• 3. King-Yin Lam A, Sze-Yan Chan S, Leung M. Synchronous colorectal cancer: Clinical, pathological and molecular implications. World J Gastroenterol 2014; 20(22): 6815-6820.
• 4. Yang J, Peng JY, Chen W. Synchronous colorectal cancer: Clinical, pathological and molecular implications. Dig Surg 2011; 28: 379-385.
• 5. Kluciński A, Pawłowski W, Krasnodębski IW. Opis przypadku. Guzy synchroniczne jelit – współwystępowanie gruczolakoraka poprzecznicy i rakowiaka jelita cienkiego. Przegl Gastroenterol 2006; 1(3): 126-128.
• 6. Latournerie M, Jooste V, Cottet V et al. Epidemiology and prognosis of synchronous colorectal cancers. Br J Surg 2008; 95: 1528-1533.
• 7. Mulder SA, Kranse R, Damhuis RA. Prevalence and prognosis of synchronous colorectal cancer: A Dutch population-based study. Cancer Epidemiology 2011; 35(5): 442-447.
• 8. Kaibara N, Koga S, Jinnai D. Synchronous and metachronous malignancies of the colon and rectum in Japan with special reference to a coexisting early cancer. Cancer 1984; 54: 1870-1874.
• 9. Mąka B, Roman P, Kurek A et al. Rzadka postać zespołu Lyncha z trzema synchronicznymi, o podobnym zaawansowaniu, ogniskami gruczolakoraka okrężnicy. Chirurgia Polska 2013; 15(1): 88-92.
• 10. Litwiniuk M, Kara I. Physical activity and cancer. OncoReview 2012; 2(4): 228-233.
• 11. Maekawa SJ, Aoyama N, Shirasaka D et al. Excessive alcohol intake enhances the development of synchronous cancerous lesion in colorectal cancer patients. Int J Colorectal Dis 2004; 19: 171-175.
• 12. Chen HS, Sheen-Chen SM. Synchronous and “early” metachronous colorectal adenocarcinoma: analysis of prognosis and current trends. Dis Colon Rectum 2000; 43(8): 1093-1099.
• 13. Katsuhiko N, Shoko K, Natsumi I et al. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology 2009; 137(5): 1609-1620.
• 14. Fernando WC, Miranda MS, Worthley DL et al. The CIMP phenotype in BRAF mutant serrated polyps from a prospective colonoscopy patient cohort. Gastroenterol Res Pract 2014; 2014: ID 374926.
• 15. Arenas RB, Fichera A, Mhoon D, Michelassi F. Incidence and therapeutic implications of synchronous colonic pathology in colorectal adenocarcinoma. Surgery 1997; 122(4): 706-710.
• 16. Langevin JM, Nivatvongs S. The true incidence of synchronous cancer of the large bowel. Am J Surg 1984; 147(3): 330-333.
• 17. Nikoloudis N, Saliangas K, Economou A et al. Synchronous colorectal cancer. Tech Coloproctol 2004; 8(1): 177-179.
• 18. Lebda-Wyborny T, Barczyk A, Pilch-Kowalczyk J. Wirtualna kolonoskopia CT – nowa metoda oceny patologii jelita grubego. Chirurgia Polska 2008; 10(2): 88-100.
• 19. Krzakowski M, Warzocha K (ed.). Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. VM Media, Gdańsk 2013.
• 20. Van Cutsem E, Cervantes A, Nordlinger B et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow- up. Ann Oncol 2014; 25(suppl. 3): iii1-iii9.
• 21. Ihnat P, Vavra P, Zonca P. Treatment strategies for colorectal carcinoma with synchronous liver metastases: Which way to go? World J Gastroenterol 2015; 21(22): 7014-7021.
• 22. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30(28): 3499-3506.
• 23. Muc-Wierzgoń M, Nowakowska-Zajdel E, Dzięgielewska-Gęsiak S et al. Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer. World J Gastroenterol 2014; 20(29): 9759-9774.

• Document Type: article